For further pan–cancer analysis, CYFIP2 was considered the most potential target both in RA and 33 kinds of tumors, which may shed the hoping light on the therapy of human immune–related diseases and even cancer. This evidence concerns the gene CYFIP2 and rheumatoid arthritis.